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D-Dimer Predicts Events in AF May 18, 2010:2225–31vidence That D-Dimer Levels Predict Subsequent Thromboembolic
nd Cardiovascular Events in Patients With Atrial Fibrillation
uring Oral Anticoagulant Therapy
Objectives The aim of the present study was to evaluate whether elevated D-dimer levels can predict subsequent thrombo-
embolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.
Background Atrial fibrillation is associated with hemostatic abnormalities even during oral anticoagulant therapy. D-dimer
levels reflect a pro-thrombogenic state and thus might serve as a marker of thromboembolic and cardiovascular
events.
Methods This was a single-center, prospective, observational study. Patients with atrial fibrillation (269 patients, age
74  9 years, 160 paroxysmal atrial fibrillation) treated with warfarin (target prothrombin time–international
normalized ratio: 1.5 to 3.0) were included. D-dimer levels were measured to assess the relationship of this pa-
rameter with subsequent thromboembolic and cardiovascular events. End points were thromboembolic events
and combined cardiovascular events (thromboembolic events, cerebral hemorrhage, myocardial infarction, car-
diovascular death).
Results D-dimer levels were elevated (0.5 g/ml) in 63 (23%) patients. During an average follow-up period of 756 
221 days, 10 (1.8%/year) thromboembolic events (8 ischemic strokes, 1 transient ischemic attack, and 1 pe-
ripheral embolism) and 27 (4.8%/year) combined cardiovascular events (10 thromboembolisms, 9 deaths from
heart failure, 3 sudden deaths, 2 myocardial infarctions, and 3 cerebral hemorrhages) occurred. Patients with
elevated D-dimer levels experienced higher thromboembolic and combined cardiovascular events. Cox propor-
tional hazard model revealed that elevated D-dimer levels were associated with both thromboembolic (p  0.01,
hazard ratio: 15.8; 95% confidence interval: 3.33 to 75.5) and combined cardiovascular (p  0.01, hazard ratio:
7.64; 95% confidence interval: 3.42 to 17.1) events.
Conclusions D-dimer might be a useful marker of both thromboembolic and cardiovascular events in patients with atrial fi-
brillation during oral anticoagulant therapy. (J Am Coll Cardiol 2010;55:2225–31) © 2010 by the American
College of Cardiology Foundatione
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strial fibrillation (AF) is associated with hemostatic abnor-
alities and increased risk of thromboembolic events. Ef-
ectiveness of oral anticoagulant therapy in reducing throm-
oembolic events is well documented (1–3); however, levels
f coagulation markers are still elevated even during oral
nticoagulant therapy in some patients (4–7). D-dimer
riginates from the formation and lysis of cross-linked fibrin
nd reflects activation of coagulation and fibrinolysis; thus,
t can be used as an “in vivo” coagulation marker in addition
o the standard “in vitro” marker of prothrombin time–
nternational normalized ratio (PT-INR). The aim of the
resent study was to evaluate whether elevated D-dimer
evels can predict subsequent thromboembolic and cardio-
ascular events in patients with AF during oral anticoagu-
ant therapy.
ethods
atients. This was a single-center, prospective, observa-
ional study. Patients eligible for our study were those
ndergoing AF treatment with warfarin. During entry
eriods (January 2006 to April 2007), 301 patients were
nitially screened, and finally 269 patients—152 (57%) male,
09 (41%) chronic AF (AF lasting more than 2 regular
ffice visits), and 160 paroxysmal (or persistent) AF—were rnrolled and followed until December 2008 (Fig. 1). The
tudy protocol was approved by the institutional ethics
ommittee, and informed written consent was obtained
rom all the patients.
lood sampling and assays. All assays were performed in
he laboratory of our institution within 2 h of blood
ampling. For the quantitative measurement of D-dimers, a
atex-enhanced photometric immunoassay (LPIA, Mitsub-
shi Chemical Medience Corporation, Tokyo, Japan) was
sed with automatic analyzer (LPIA-S500). The detection
imit of this assay was 0.3 g/ml. Intra-assay and interassay
ariability (coefficient of variability) was 2.2% and 4.4%,
espectively. D-dimer was measured at the time of enroll-
ent and repeated 2 or 3 times during entry period in some
atients. The PT-INR was measured every 1 to 2 month
hroughout the observational periods. Target PT-INR was
et at 1.5 to 3.0.
nd points. The end points were thromboembolic events
ischemic stroke, transient ischemic attack, peripheral em-
olism) and combined cardiovascular events, which in-
luded thromboembolic events, cerebral hemorrhage, myo-
ardial infarction, and cardiovascular deaths. Major bleeding
as defined as gastrointestinal bleeding requiring transfu-
ion and intracranial bleeding, including cerebral hemor-
hage and subdural hematoma.
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May 18, 2010:2225–31 D-Dimer Predicts Events in AFtatistical analysis. Data were presented as the mean 
D or percentages, as appropriate. Event frequencies were
ompared with the chi-square test. Other comparisons
etween 2 groups of data were made with unpaired Student
test or Mann-Whitney U test, as appropriate. Correlation
nalysis was performed by Spearman’s rank correlation. The
ptimal D-dimer cutoff point was evaluated by receiver
Figure 1 Flow Chart Illustrating
Participants and Exclusions in This Study
haracteristics of Patients With High D-Dimer LevelsTable 1 Characteristics of Patients With High D-Dimer Levels
All Patients
(n  269)
D-Dim
Age (yrs) 74 9
Male (%) 57
Chronic atrial fibrillation (%) 41
CHF (%) 42
Hypertension (%) 56
Age 75 yrs (%) 47
Diabetes mellitus (%) 23
History of stroke (%) 12
Cardiovascular events (n) 27
Thromboembolic events (n) 10
Death from heart failure (n) 9
Sudden death (n) 3
Myocardial infarction (n) 2
Cerebral hemorrhage (n) 3
Bleeding complications (n) 9
Gastrointestinal bleedings (n) 5
hromboembolic events: ischemic stroke, transient ischemic attack, and peripheral embolism. Card
erebral hemorrhage. Bleeding complications: gastrointestinal bleeding requiring transfusion and intracr
CHF  congestive heart failure (New York Heart Association functional class II).perator characteristic curve. Lo-
istic regression models were ap-
lied to assess the determinants
f high D-dimer levels. The out-
omes were displayed with
aplan-Meier event-free curve
nd compared with the use of
og-rank tests. The prognostic
alues of D-dimer and clinical
ariables were analyzed with
ox-proportional hazard mod-
ls. A value of p  0.05 was accepted as statistically
ignificant. The statistical software package SPSS (version
1.0, SPSS, Inc., Chicago, Illinois) and StatView (version
.0 StatView, Berkeley, California) were used for analyses.
esults
aseline clinical characteristics. Baseline heart disease
ncluded 44 (16%) hypertensive heart disease, 37 (14%)
oronary artery disease, 32 (12%) valvular heart disease, 17
6.3%) hypertrophic cardiomyopathy, and 10 (3.7%) dilated
ardiomyopathy. No apparent heart diseases were found in
31 (49%) patients. Other clinical risk factors are shown in
able 1.
At the time of enrollment, PT-INR levels were 1.93 
.53 (1.2 to 6.9, median 1.82). The PT-INR levels were less
ptimal (1.5) in 32 (12%), exceeded (3.0) in 7 (2.6%),
nd within therapeutic range (1.5  PT-INR 3.0) in the
emaining 230 (86%) patients (Fig. 2). Linear regression
nalysis revealed no relationship between D-dimer levels
nd PT-INR (p  0.17,   0.084 by Spearman’s rank
orrelation), consistent with the previous report (5). At the
nd of follow-up, PT-INR levels were 1.94  0.60 (1.0 to
Abbreviations
and Acronyms
AF  atrial fibrillation
CHF  congestive heart
failure
CI  confidence interval
PT-INR  prothrombin
time–international
normalized ratio
0.5 g/ml)
63)
D-Dimer (<0.5 g/ml)
(n  206) *p Value
 8 72 9 0.01
6 57 0.86
9 39 0.19
7 35 0.01
2 57 0.54
1 39 0.01
5 23 0.67
1 9 0.01
8 9 0.01
8 2 0.01
6 3 0.01
0 3 0.34
2 0 0.010
2 1 0.075
8 1 0.01
5 0 0.01
ular events: thromboembolism, death from heart failure, sudden death, myocardial infarction, and
anial bleeding. *p value, D-dimer 0.5 g/ml versus D-dier (>
(n 
79
5
4
6
5
7
2
2
1
iovasc
mer 0.5 g/ml.
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D-Dimer Predicts Events in AF May 18, 2010:2225–31.0, median 1.86) and were within therapeutic range in 82%
f the patients.
eproducibility of the D-dimer levels. Serial measure-
ents of D-dimer levels to assess reproducibility with
imilar PT-INR levels (1.86 038, median 1.82, vs. 1.97
.42, median 1.90, p  0.055) were available in 105
atients. There was a high correlation between the 2
-dimer measurements (p 0.01,  0.86, by Spearman’s
ank correlation). The difference between these 2 D-dimer
easurements was small (0.21  0.42 g/ml, median 0.01
g/ml).
nd points and major bleedings. Approximately 80% of
he patients were followed in our institution, and the rest
ere followed by attending physicians who referred the
Figure 2 Relationship Between Anticoagulation
Intensity and D-Dimer Levels
D-dimer levels are shown with a logarithmic scale. D-dimer levels were ele-
vated (0.5 g/ml) in 63 (23%) patients with 86% proper prothrombin
time–international normalized ratio (PT-INR) levels. Regression analysis
revealed no relationship between D-dimer levels and PT-INR. D-dimer values
below the detection limits of 0.3 g/ml (n  154) were shown on the bottom
line (0.1).
Figure 3 Receiver Operator Characteristic Curve for D-Dimer to
Area under receiver operator characteristic curve for thromboembolic events (A) a
Arrows indicate D-dimer cutoff values. The optimum cutoff point, identified as theatients to us. During a follow-up time of 756  221 (1 to
,091; median 740) days, 4 patients discontinued taking
arfarin, and 6 were lost to follow-up after 1 year. These 10
atients were included in the final analysis (Fig. 1). There
ere 10 thromboembolic events (1.8%/year): 8 ischemic
trokes, 1 transient ischemic attack, and 1 peripheral em-
olism. There were 27 cardiovascular events (4.8%/year): 10
hromboembolisms, 9 deaths from heart failure, 3 sudden
eaths, 2 myocardial infarctions, and 3 cerebral hemor-
hages. There were 9 (1.6%/year) major bleedings: 3 cere-
ral hemorrhages, 1 subdural hematoma, and 5 gastrointes-
inal bleedings requiring transfusion (Table 1).
utoff values and determinants of D-dimer levels. In the
urrent study, the upper quartile of the D-dimer value was
.48 g/ml. With the receiver operator characteristic curve
nalysis (Fig. 3), the optimum cut point, identified as the
oint closest to upper left corner, yielded optimal cutoff
alue of approximately 0.5 g/ml to detect both thrombo-
mbolic events and cardiovascular events. Previously, most
tudies used D-dimer cutoff values of 0.5 to 1.0 g/ml for
xcluding pulmonary embolism (8) and acute aortic dissec-
ion (9). On the basis of these findings, the cutoff value of
-dimer level for the current study was set at 0.5 g/ml.
edian values in patients with high (0.5 g/ml) and low
0. 5 g/ml) D-dimer values were 0.86 and 0 g/ml,
espectively. The PT-INR levels in patients with high and
ow D-dimer levels were not different (1.99  0.74, median
.82, vs. 1.92  0.45, median 1.82, p  0.83 by Mann-
hitney U test). Table 1 shows characteristics of patients
ith high (0.5 g/ml) D-dimer levels. Patients with high
-dimer levels had higher prevalence of congestive heart
ailure (CHF), older age (75 years), and history of stroke.
able 2 shows determinants of high D-dimer levels by
ogistic regression analysis. Univariate analysis showed that
HF, age 75 years, and history of stroke were the
ict Thromboembolic and Cardiovascular Events
iovascular events (B) was 0.82 and 0.74, respectively.
losest to upper left corner, was 0.54 g/ml (A) and 0.50 g/ml (B).Pred
nd card
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May 18, 2010:2225–31 D-Dimer Predicts Events in AFignificant determinants of high D-dimer levels. Multivar-
ate analysis including these 3 parameters, and PT-INR
alues revealed that these 3 parameters were the indepen-
ent predictors of high D-dimer levels.
igh D-dimer levels to predict thromboembolic and
ardiovascular events. There were 8 thromboembolic
vents observed among patients with baseline D-dimer
evels 0.5 g/ml as compared with 2 such events in those
ith baseline D-dimer levels 0.5 g/ml. Kaplan-Meier
hromboembolic event-free curves for D-dimer level
howed that elevated D-dimer level was the significant
redictor of subsequent thromboembolic events (Fig. 4).
tatistical significance of separation between the 2 groups
as achieved at 600 days. With regard to PT-INR levels at
he time of events, 5 (50%) of the 10 thromboembolic
eterminants of High D-Dimer Levels (>0.5 g/ml) by Logistic ReTable 2 Determinants of High D-Dimer Levels (>0.5 g/ml) by
n
D-Dimer Le
Risk ()
Univariate analysis
Male 152 0
Chronic atrial fibrillation 109 0
Congestive heart failure 114 0.36
Hypertension 150 0
Age 75 yrs 126 0.36
Diabetes mellitus 63 0
History of stroke 33 0.35
PT-INR (continuous variable)
Multivariate analysis
Congestive heart failure
Age 75 yrs
History of stroke
PT-INR (continuous variable)
I  confidence interval; PT-INR  prothrombin time–international normalized ratio.
Figure 4 Kaplan-Meier Thromboembolic Event-Free Curves for
D-Dimer Levels During Oral Anticoagulant Therapy
Thromboembolic events are defined as ischemic stroke, transient ischemic
attack, and peripheral embolism. D-dimer level was the significant predictor of
subsequent thromboembolic events. Statistical significance of separation
between the 2 groups was achieved at 600 days.Avents occurred when the PT-INR levels were 1.5, and
nly 1 thromboembolic event took place when the PT-INR
evel exceeded 2.0. Table 3 shows risk factors for thrombo-
mbolic events by Cox proportional hazard analysis. Uni-
ariate analysis showed that high D-dimer levels, CHF, and
istory of stroke were associated with increased thrombo-
mbolic events. High D-dimer level was the significant
eterminant after adjustment of baseline PT-INR (p 
.01, hazard ratio: 15.8; 95% confidence interval [CI]: 3.33
o 75.5). Fully-adjusted models were not possible, given the
ow number of events.
There were 18 combined cardiovascular events observed
mong patients with baseline D-dimer levels 0.5 g/ml,
s compared with 9 such events in those with low levels.
aplan-Meier curves showed that high D-dimer level was
he significant predictor of subsequent cardiovascular events
Fig. 5). Statistical significance of separation between the 2
roups was achieved at 600 days. Table 4 shows risk factors
or combined cardiovascular events by Cox proportional
azard analysis. High D-dimer level, CHF, age 75 years,
iabetes mellitus, and history of stroke were associated with
ncreased cardiovascular events. High D-dimer level was
lso a significant determinant after adjustment of baseline
ion Analysisstic Regression Analysis
edian, g/ml)
p Value Odds Ratio (95% CI)Risk ()
0 0.86
0 0.16
0 0.01 3.72 (2.05–6.76)
0 0.54
0 0.01 3.86 (2.01–7.13)
0 0.67
0 0.01 2.81 (1.32–6.01)
0.36
0.01 2.87 (1.53–5.38)
0.01 3.14 (1.66–5.95)
0.045 2.29 (1.02–5.16)
0.99 1.00 (0.60–1.67)
isk Factors for Thromboembolic Eventsy Cox Pr portional Hazard AnalysisTable 3 Risk Factors for Thromboembolic Eventsby Cox Proportional Hazard Analysis
p Value Hazard Ratio (95% CI)
D-dimer 0.5 g/ml 0.01 15.7 (3.31–74.0)
PT-INR at baseline 0.17
Male 0.30
CHF 0.012 14.1 (1.78–111)
Hypertension 0.36
Age 75 yrs 0.36
Diabetes mellitus 0.60
History of stroke 0.01 9.69 (2.80–33.6)gressLogi
vels (Mbbreviations as in Table 2.
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D-Dimer Predicts Events in AF May 18, 2010:2225–31T-INR (p  0.01, hazard ratio: 7.64; 95% CI: 3.42 to
7.1). Fully-adjusted models were not performed, given the
ow number of combined cardiovascular events.
With regard to bleeding complications, 4 (44%) of the 9
vents occurred when the PT-INR levels were 3.0, but 3
33%) events occurred when the PT-INR levels were 2.0
i.e., 1.25, 1.55, 1.86). There were 8 bleeding complications
bserved among patients with baseline D-dimer levels 0.5
g/ml, as compared with 1 such event in those with low
evels. Cox proportional analysis revealed that high D-dimer
evels were significant correlates of bleeding complications
p  0.01, hazard ratio: 29.3; 95% CI: 3.65 to 235) after
djustment of baseline PT-INR.
aroxysmal versus chronic AF. Prevalence of CHF (52%
s. 36%, p  0.01) and history of stroke (17% vs. 8%, p 
.021) were higher in chronic AF than those in paroxysmal
F. However, prevalence of high D-dimer levels (28% vs.
1%, p  0.19) were comparable between these 2 groups.
iscussion
t is well known that D-dimer levels are increased in
atients with AF, and introduction of warfarin decreases
-dimer levels (4). However, D-dimer levels are still
levated even during oral anticoagulant therapy in some
atients (4–7). We have found that they were the high-risk
atients who subsequently suffer thromboembolic and car-
iovascular events.
linical significance of D-dimer measurement. Circulat-
ng concentration of fibrin D-dimer levels reflect the extent
f fibrin turnover. Highly elevated D-dimer values occur in
arious disorders in which the coagulation system is exces-
ively activated, such as acute venous thromboembolism (8)
nd acute aortic dissection (9). It has been suggested that
Figure 5
Kaplan-Meier Combined
Cardiovascular Event-Free Curves for
D-Dimer Levels During Oral Anticoagulant Therapy
Combined cardiovascular events are defined as thromboembolic events, cere-
bral hemorrhage, myocardial infarction, or cardiovascular death. D-dimer level
was the significant predictor of subsequent combined cardiovascular events.
Statistical significance of separation between the 2 groups was achieved at
600 days.odestly elevated circulating D-dimer values reflect minor Ancreases in blood coagulation, thrombin formation, and
urnover of cross-linked intravascular fibrin. These increases
ight be related to thromboembolic (6) and cardiovascular
7) events. This study was consistent with these results.
nterestingly, elevated D-dimer levels also predicted bleed-
ng complications in this study. The reasons were not
nown, but it can be speculated that the fibrinolytic activa-
ion of which D-dimer is a marker might itself predispose to
leeding.
tudy limitations. First, this is a single-center study, and
election bias is a major concern. We have tried to include
very patient with AF who visited our office; however, it is
ifficult to start anticoagulation therapy in elderly patients
ith dementia, for fear of overdoses of warfarin, frequent
alls, and subsequent bleeding complications. Age 75
ears was not a risk factor for thromboembolic events partly
ue to the exclusion of these high-risk patients. Second,
arget PT-INR in this study was set below the recom-
ended guideline of Western countries (PT-INR: 2.0 to
.0). The Japanese Secondary Prevention Trial (10) sug-
ested that there might be a racial difference in the optimal
nticoagulation intensity for the prevention of ischemic
troke in patients with AF. Japanese guidelines (11) recom-
ended target PT-INR should be 1.6 to 2.6 when the
atients were older than 70 years. Anticoagulant therapies
hould always be considered along with the balance between
ntithrombotic effect and risk of bleeding. The annual
ncidence of thromboembolic events (1.8%/year) and bleed-
ng complications (1.6%/year) were similar in this study,
uggesting that target PT-INR was probably a reasonable
ange for the Japanese population. However, it might not be
pplicable to Western populations. Third, it is speculated
hat D-dimer levels might be increased at the time of events,
ut it was measured only at the entry periods, mainly due to
udget constraints. Therefore, D-dimer levels at the time of
vents were unknown. However, reproducibility of D-dimer
evels was acceptable in our study as well as in a previous
tudy (5); thus we believe that D-dimer levels at baseline, if
nticoagulated in a proper PT-INR range, are an important
arker of thromboembolic and cardiovascular events. Fi-
ally and most importantly, the number of patients and
vents in this study was small; therefore further larger-scale,
ulticenter studies are needed to confirm these findings.
isk Factors for Combined Cardiovascular Eventsy Cox Pr portional Hazard AnalysisTable 4 Risk Factors for Combined Cardiova cular Eventsby Cox Proportional Hazard Analysis
p Value Hazard Ratio (95% CI)
D-dimer 0.5 g/ml 0.01 7.57 (3.39–16.9)
PT-INR at baseline 0.30
Male 0.35
Congestive heart failure 0.01 19.2 (4.54–80.9)
Hypertension 0.45
Age 75 yrs 0.01 3.49 (1.48–8.26)
Diabetes mellitus 0.01 3.05 (1.43–6.50)
History of stroke 0.01 6.25 (2.90–13.5)bbreviations as in Table 2.
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May 18, 2010:2225–31 D-Dimer Predicts Events in AFonclusions
levation of D-dimer levels despite proper anticoagulant
herapy can predict thromboembolic and cardiovascular
vents in patients with AF. Whether thromboembolic and
ardiovascular events in patients with AF can be prevented
y increasing anticoagulation intensity with the help of
-dimer levels remains to be elucidated.
eprint requests and correspondence: Dr. Tsuneaki Sadanaga,
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